@article {McInnes829, author = {Lachlan E. McInnes and Carleen Cullinane and Peter D. Roselt and Susan Jackson and Benjamin J. Blyth and Ellen M. van Dam and Nicholas A. Zia and Matthew J. Harris and Rodney J. Hicks and Paul S. Donnelly}, title = {Therapeutic Efficacy of a Bivalent Inhibitor of Prostate-Specific Membrane Antigen Labeled with 67Cu}, volume = {62}, number = {6}, pages = {829--832}, year = {2021}, doi = {10.2967/jnumed.120.251579}, publisher = {Society of Nuclear Medicine}, abstract = {Radionuclide therapy targeting prostate-specific membrane antigen (PSMA) is promising for prostate cancer. We previously reported a ligand, 64Cu-CuSarbisPSMA, featuring 2 lysine-ureido-glutamate groups. Here, we report the therapeutic potential of 67Cu-CuSarbisPSMA. Methods: Growth of PSMA-positive xenografts was evaluated after treatment with 67Cu-CuSarbisPSMA or 177Lu-LuPSMA imaging and therapy (I\&T). Results: At 13 d after injection, tumor growth was similarly inhibited by the 2 tracers in a dose-dependent manner. Survival was comparable after single (30 MBq) or fractionated (2 {\texttimes} 15 MBq, 2 wk apart) administrations. Conclusion: 67Cu-CuSarbisPSMA is efficacious in a PSMA-expressing model of prostate cancer.}, issn = {0161-5505}, URL = {https://jnm.snmjournals.org/content/62/6/829}, eprint = {https://jnm.snmjournals.org/content/62/6/829.full.pdf}, journal = {Journal of Nuclear Medicine} }